Institution statistics

NOVARTIS PHARMA AG - Switzerland 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:300-400
Total Number of Projects:200-300
2018
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:> 1000
Total Number of Projects:300-400
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2010
Criterium:Position:
Overall Score:300-400
Total Project Funding per Partner:500-600
Total Number of Projects:800-900
Total Project Funding:600-700
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:200-300
Diversity Index:500-600
2009
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:700-800
2008
Criterium:Position:
Overall Score:200-300
Total Project Funding per Partner:300-400
Total Number of Projects:400-500
Total Project Funding:300-400
Networking Rank (Reputation):500-600
Partner Constancy:> 1000
Project Leadership Index:200-300
Diversity Index:500-600
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 62
As coordinator: 1
As participant: 61
Sole participant: 0
Coordinator / Participant Ratio: 0.02*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 33.734.493 281.277 4
2019 0 191.537.251 0 14
2018 0 169.338.471 0 9
2017 0 86.418.205 0 8
2016 0 29.414.923 530.454 6
2015 24.331.609 3.950.971 0 1 1
2012 0 3.935.114 528.884 1
2011 0 4.246.947 244.781 1
2010 0 17.757.048 547.100 2
2009 0 1.700.000 100.000 1
2008 0 25.854.986 1.913.401 5
2006 0 4.980.000 661.786 2
2005 0 24.574.185 758.063 3
2004 0 2.259.754 173.827 1
2001 0 85.980 10.748 1
2000 0 3.536.341 341.972 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
JANSSEN PHARMACEUTICA NV24
PFIZER LIMITED22
F HOFFMANNLA ROCHE18
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT17
ELI LILLY AND COMPANY LIMITED16
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD16
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE15
KATHOLIEKE UNIVERSITEIT LEUVEN13
TAKEDA DEVELOPMENT CENTRE EUROPE11
UCB BIOPHARMA11
NOVO NORDISK10
SANOFIAVENTIS10
BAYER AKTIENGESELLSCHAFT9
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG9
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER9
KING'S COLLEGE LONDON9
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE9
UNIVERSITAIR MEDISCH CENTRUM UTRECHT9
UNIVERSITY OF NEWCASTLE UPON TYNE9
ABBVIE INC8
ASTRAZENECA8
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM8
KAROLINSKA INSTITUTE8
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN8
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS7
ASTRAZENECA AB7
BAYER7
CHARITE UNIVERSITAETSMEDIZIN BERLIN7
EUROPEAN PATIENTS' FORUM7
MERCK SHARP & DOHME CORP7
RIJKSUNIVERSITEIT GRONINGEN7
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT7
STICHTING KATHOLIEKE UNIVERSITEIT7
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL7
THE UNIVERSITY OF MANCHESTER7
UNIVERSITY COLLEGE LONDON7
UPPSALA UNIVERSITET7
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE6
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN6
STICHTING VUMC6
TEVA PHARMACEUTICAL INDUSTRIES LIMITED6
UNIVERSITY OF AARHUS6
UNIVERSITY OF COPENHAGEN6
ACADEMISCH ZIEKENHUIS GRONINGEN5
EBERHARD KARLS UNIVERSITAET TUEBINGEN5
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V5
INSTITUT DE RECHERCHES SERVIER5
MEDIZINISCHE UNIVERSITAET WIEN5
THE UNIVERSITY OF LIVERPOOL5
ACADEMISCH ZIEKENHUIS LEIDEN4
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE4
CHRISTIAN ALBRECHTS UNIVERSITAET ZU KIEL4
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK4
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS4
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE4
EUROPEAN MOLECULAR BIOLOGY LABORATORY4
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA4
H LUNDBECK AS4
LUNDS UNIVERSITET4
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE4
OSPEDALE PEDIATRICO BAMBINO GESU4
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON4
SANOFIAVENTIS DEUTSCHLAND4
SERVICIO MADRILENO DE SALUD4
STICHTING LYGATURE4
STICHTING VU4
THE HYVE BV4
THE UNIVERSITY OF EDINBURGH4
THE UNIVERSITY OF SHEFFIELD4
UNIVERSITA DEGLI STUDI DI FIRENZE4
UNIVERSITAET BERN4
UNIVERSITAET ZUERICH4
UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANSUNIVERSITAT4
UNIVERSITY OF BIRMINGHAM4
UNIVERSITY OF BOLOGNA4
UNIVERSITY OF DUNDEE4
UNIVERSITY OF WALES CARDIFF4
ALLERGAN LIMITED3
ALZHEIMER EUROPE3
AMGEN LIMITED3
BAYER PHARMA3
BRISTOLMYERS SQUIBB COMPANY CORP3
CELGENE MANAGEMENT SARL3
COMMISSARIAT A L'ENERGIE ATOMIQUE3
CONSIGLIO NAZIONALE DELLE RICERCHE3
COVANCE LABORATORIES3
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE3
EUROPEAN CANCER PATIENT COALITION3
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON INSTITUT DE RECERCA3
FUNDACIO SANT JOAN DE DEU3
GRUNENTHAL3
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE3
INSTITUT PASTEUR3
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV3
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV3
MEDIZINISCHE HOCHSCHULE HANNOVER3
NOLDUS INFORMATION TECHNOLOGY BV3
REGION HOVEDSTADEN3
SERVICIO ANDALUZ DE SALUD3
STICHTING BURO ECNP3
Constancy:

Total number of partners:1437

Partner loyalty:
Frequent Partner: (> 2 projects): 663
Rare Partner: 774

Frequent / Rare Partner Ratio: 0.86

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES13
RTD HORIZONTAL TOPICS9
INDUSTRY AND TECHNOLOGY5
SOCIAL AND ECONOMIC CONCERNS2
PROTECTING MAN AND HIS ENVIRON1

Project overview:

Start dateProjectacronymrolefundingpartners
2020-07-01C-H Activation for Industrial Renewal CHAIRparticipant3.944.74413
2020-05-01Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA INNODIA HARVESTparticipant5.999.05540
2020-01-01Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies ImmUniverseparticipant15.500.00026
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69428
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-11-01EU Patient- cEntric clinicAl tRial pLatform EU-PEARLparticipant12.004.95336
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00022
2019-09-01Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials Trials@Homeparticipant19.036.99831
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-04-01Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement MOBILISE-Dparticipant25.395.89734
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-03-01Neurotoxicity De-Risking in Preclinical Drug Discovery NeuroDeRiskparticipant5.331.00018
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2019-01-01Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain IM2PACTparticipant9.000.00027
2019-01-01Remote Assessment of Disease and Relapse – Alzheimer’s Disease RADAR-ADparticipant4.999.75716
2019-01-01NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients NECESSITYparticipant8.200.00026
2019-01-01FAIRplus FAIRplusparticipant3.996.15022
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-10-01Peroxisome Interactions and Communication PERICOparticipant3.974.52715
2018-09-01WEB-RADR 2 WEB-RADR 2participant1.168.75011
2018-09-01Ensuring the future of EUPATI beyond 2020 EFOEUPATIparticipant365.24312
2018-07-01Research empowerment on solute carriers (ReSOLUTE) ReSOLUTEparticipant12.000.00014
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-04-01Improving the care of patients suffering from acute or chronic pain IMI-PainCareparticipant11.225.27140
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88156
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 MACUSTARparticipant8.025.00013
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-03-01Big Data 4 Better Hearts - Sofia ref.: 116074 BigData Heartparticipant9.664.97019
2017-03-01Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 IMPRiNDparticipant4.684.99819
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-03-01Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases CaSR Biomedicineparticipant3.657.19518
2016-03-01FRAGments training NETwork FRAGNETparticipant3.842.48213
2016-01-01Accelerated Early staGe drug diScovery AEGISparticipant3.836.99626
2015-09-01Connected Health Early Stage Researcher Support System CHESSparticipant3.950.97118
2015-08-01iABC Programme IABC PROGRAMMEcoordinator24.331.60922
2012-01-01Novel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic Reviews MEDIASRESparticipant3.935.11410
2011-11-01"""RNPnet"" - RNP structure, function and mechanism of action" RNPnetparticipant4.246.94714
2010-04-01European Project on Mendelian Forms of Parkinson’s Disease MEFOPAparticipant5.759.46823
2010-01-01Activation of vasculature associated stem cells and muscle stem cells for the repair and maintenance of muscle tissue Endostemparticipant11.997.58022
2009-07-01Integrating nanomaterials in formulations INFORMparticipant1.700.00017
2008-12-01Promotion of plasticity as a treatment for neurodegenerative conditions PLASTICISEparticipant5.199.44516
2008-10-15Initial training network on therapeutic approaches and predictive models for neurodegenerative diseases NEUROMODELparticipant2.544.49211

overview shows latest 50 from 62 projects (2000-01-01 - 2020-12-31)
A full list of projects can be found here:

Alias institution names:
  • NOVARTIS PHARMA

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum